Clinical experience with cyclosporine and azathioprine at Brigham and Women's Hospital.
Cyclosporine (CsA) immunosuppressive therapy of renal allograft recipients at Brigham and Women's Hospital yielded a 20% increase in 12- and 24-month allograft survival over azathioprine (Aza) treated controls. A trend towards increased allograft survival with better HLA-A,B, or DR matching in recipients of cadaver allografts treated with CsA was appreciated, but it fell short of statistical significance. Nephrotoxicity is common in CsA-treated patients and is manifested by a largely reversible increase in the serum creatinine. It is possible to convert patients from CsA to Aza without adverse effects on allograft survival or allograft function.
D000328:Adult; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use*; D002102:Cadaver; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003404:Creatinine / Q000097:blood; D003524:Cyclosporins / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D006680:HLA Antigens; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation; D007683:Kidney Tubular Necrosis, Acute / Q000209:etiology; D011184:Postoperative Period; D013997:Time Factors
D003524:Cyclosporins; D006680:HLA Antigens; D003404:Creatinine; D001379:Azathioprine